CAM
RIGL icon

ClariVest Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

ClariVest Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-14,870
Closed -$354K – 742
2016
Q4 		$354K Sell
14,870
-2,165
-13% -$62K 0.01% 436
2016
Q3 		$626K Buy
17,035
+3,515
+26% +$101K 0.02% 361
2016
Q2 		$301K Buy
13,520
+710
+6% +$17.7K 0.01% 424
2016
Q1 		$267K Buy
12,810
+1,740
+16% +$42.9K 0.01% 430
2015
Q4 		$335K Buy
11,070
+1,810
+20% +$54.9K 0.01% 394
2015
Q3 		$228K Buy
9,260
+60
+0.7% +$1.79K 0.01% 410
2015
Q2 		$295K Buy
+9,200
New +$351K 0.01% 374

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClariVest Asset Management's RIGL Position: Q1 2017 in Review

ClariVest Asset Management sold out of Rigel Pharmaceuticals (RIGL) in Q1 2017, closing a stake of 14,870 shares — an estimated $354K sold.

ClariVest Asset Management first reported a position in RIGL in Q2 2015 and held it in 7 quarters. The position peaked at $626K in Q3 2016. 99 funds tracked by Wall St. Rank hold RIGL as of Q1 2017.

  • ClariVest Asset Management reported no remaining Rigel Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • ClariVest Asset Management sold 14,870 Rigel Pharmaceuticals shares in Q1 2017, an estimated $354K.
  • ClariVest Asset Management first reported a position in Rigel Pharmaceuticals in Q2 2015 and held it in 7 quarters.
  • ClariVest Asset Management's Rigel Pharmaceuticals position peaked at $626K in Q3 2016.
  • 99 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2017.

Based on ClariVest Asset Management's 13F filing for Q1 2017, filed 11 May 2017.